Neurotrophic factor delivery as a protective treatment for glaucoma

Thomas V. Johnson, Natalie D. Bull, Keith R. Martin

Research output: Contribution to journalArticle

Abstract

Glaucoma is a progressive optic neuropathy and a major cause of visual impairment worldwide. Neuroprotective therapies for glaucoma aim to ameliorate retinal ganglion cell degeneration through direct or indirect action on these neurons. Neurotrophic factor (NTF) delivery is a key target for the development of potential neuroprotective glaucoma treatments. This article will critically summarize the evidence that NTF deprivation and/or dysfunction plays a role in the pathogenesis of glaucoma. Experimental support for the neuroprotective potential of NTF supplementation in animal models of glaucoma will be reviewed, in particular for brain-derived neurotrophic factor, ciliary neurotrophic factor, and glial cell line-derived neurotrophic factor. Finally, the challenges of clinical translation will be considered with an emphasis on the most promising NTF delivery strategies including slow-release drug delivery, gene therapy, and cell transplantation.

Original languageEnglish (US)
Pages (from-to)196-203
Number of pages8
JournalExperimental eye research
Volume93
Issue number2
DOIs
StatePublished - Aug 1 2011
Externally publishedYes

Keywords

  • Cell transplantation
  • Gene therapy
  • Glaucoma
  • Neuroprotection
  • Neurotrophic factor
  • Neurotrophin
  • Slow release

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Neurotrophic factor delivery as a protective treatment for glaucoma'. Together they form a unique fingerprint.

  • Cite this